Live Breaking News & Updates on On small cell lung cancer

Stay informed with the latest breaking news from On small cell lung cancer on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in On small cell lung cancer and stay connected to the pulse of your community

Alectinib: Adjuvant Treatment for Lung Cancer Approved by US FDA

Alectinib approved by US FDA for auxiliary treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who underwent tumor resection.

Israel , United-kingdom , Canada , Australia , Australian , Israel-ministry-of-health , Australian-therapeutic-goods-administration , Genentech-inc , Drug-administration-on , Regulatory-agency , Oncology-center

EFFECTOR Reports Results Of Phase2 KICKSTART Trial Of Tomivosertib-Pembrolizumab In NSCLC

eFFECTOR Therapeutics, Inc. (EFTR) announced Thursday topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (NSCLC) with PD-L1 =50%.

Basilea , Basel-stadt , Switzerland , United-states , London , City-of , United-kingdom , T-inc , Intel-corp , Intel , Nasdaq-stock-exchange

Why Novocure Stock Is Jumping Today

Novocure had good news mixed with some not-so-good news.

Miami , Florida , United-states , Minesh-mehta , Miami-cancer-institute , Tumor-treating-fields , Motley-fool-stock-advisor , Stock-advisor , Brain-metastases , Ovocure , Otley-fool-stock-advisor

Focusing on oncogenic driver mutations and resistance mechanisms in the treatment of NSCLC

Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for patients with advanced stages.

Higher-education , Cancer , Ell , Ung-cancer , On-small-cell-lung-cancer , Mall-cell-lung-cancer , Iomarker , Rugs , Xon , Ene , Rowth-factor

Tislelizumab Receives CHMP Recommendation for First- and Second-Line Treatment of NSCLC

The European Medicines Agency’s CHMP has recommended the approval of tislelizumab in the first- and second-line for non–small cell lung cancer.

China , Mark-lanasa , China-national-medical-products-administration , European-union , European-medicines-agency , Medicinal-products , Human-use , Solid-tumors , Thoracic-oncology , D , Hd , Tislelizumab

Genetic signature may help predict disease-free survival in patients with non-small cell lung cancer

A new study identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation.

Cell-reports-medicine , Cancer , Ell , Mmunotherapy , Ung-cancer , On-small-cell-lung-cancer , Mall-cell-lung-cancer , Ene , Ene-expression , Enes , Edicine

NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcript

NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcript February 22, 2024 NovoCure Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. Welcome to the NovoCure Q4 2023 Earnings Conference Call. At this […]

France , Germany , California , United-states , New-york , German , French , Jason-bednar , Ashley-cordova , Los-angeles , Piper-sandler , Optune-gio

Green tea does not lower the risk of lung cancer

Whether green tea consumption was associated with a lower risk of lung cancer.

China , United-kingdom , Cancer , Reen-tea , Ung-cancer , Ea , Nti-inflammatory , Ell , Iet , Enetic , Enome

Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Call Transcript

Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Call Transcript February 20, 2024 Summit Therapeutics Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome to Summit’s Fourth Quarter and Year End 2023 Earnings Call. [Operator Instructions] Please […]

United-states , Prague , Praha , Hlavníesto , Czech-republic , California , Canada , China , Japan , Santa-monica , Chinese , Dave-gancarz

Combination therapy offers breakthrough in NSCLC treatment

A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.

Texas , United-states , John-heymach , University-of-texas-md-anderson-cancer-center , Anderson-cancer , Nature-medicine , Neck-medical , Biomarker , Ancer , Mmunotherapy , Ung-cancer , Ntibody